From General Motors, Ford's Lightning pickup, to Tesla's Cybertruck

Chip shortage makes General Motors no longer the top seller of vehicles in the US, as of January 4, 2022. Toyota, which reportedly sold about 114,000 more vehicles than GM in 2021. GM reported that total sales were down almost 13 percent last year due to semiconductor shortages and GM has had to cut features from some vehicles, such as wireless chargers and HD radios, due to supply issues. (Source: https://www.theverge.com/2022/1/4/22867285/gm-toyota-us-top-selling-automaker-chip-shortage)

Meanwhile, GM on last Tuesday (1/4/2022) introduced CarBravo, a website that will list all the used car inventory across GM's participating dealerships as well as used cars owned by GM and its finance arm. According to the news that I am reading, there are 400,000 used vehicles in dealer inventory on an ongoing basis. For sure, this will promote GM's business. Currently, dealers sell about 2.5 million used cars a year. GM and GM Financial have an additional 500,000 used cars in stock each year. (https://www.freep.com/story/money/cars/general-motors/2022/01/11/gm-carbravo-used-vehicle-car-retail-carmax-carvana/9171201002/) 

 Another source points out that GM made it the rule that lease holders could no longer sell their vehicles outside the GM dealership network at the end of the term, which should help to bolster the available inventory on CarBravo. (https://www.caranddriver.com/news/a38738514/gm-launches-carbravo-sales-website/) 

 Andrew Bary, Barron, named GM as one of his top stock picks for 2022, he believes General Motors is fast becoming one of the most exciting players in the electric-vehicle space. (https://www.barrons.com/articles/buy-gm-stock-pick-evs-51642111070) 

 Well, I won't disagree with him. On the other hand, Ford and Tesla are also key players in the EV industry. Ford CEO Jim Farley, leading the company’s battery vehicle plans, said in late 2021 that it would double production of both the fast-selling Mach-E electric crossover to 80,000 units in 2022. Then later he claimed that Ford would also boost its annual production target for the new F-150 Lightning pickup to 150,000 units from a previous 80,000-truck goal. According to another news that I am reading, Ford didn’t design a completely new platform for the Lightning, it simply modifies its existing F-150 design. This decision has enabled Ford to move FASTER to market. The Lightning, unveiled in May 2021, starts with a base price of $39,974 (before federal and state incentives) and driving range of 230 miles per charge. Top-end models will cost more than $90,000. Tesla CEO Elon Musk also promised that the Cybertruck would have a base price of $39,900 and a range of 250 miles per charge. (https://www.forbes.com/sites/alanohnsman/2022/01/13/fords-amped-up-electric-vehicle-strategy-boost-shares-tops-gms-market-cap/?sh=4b0a533b365c) 

But,Recently, reference to a 2022 production schedule was scrubbed from its website, production of the vehicle won’t begin until the first quarter of 2023. （https://www.theverge.com/2022/1/13/22881646/tesla-cybertruck-production-date-2022-removed-website）

【The World】IKO IKO 你聽過冇

我第一次見到以下嘅片段，我就鍾意咗IKO IKO呢首歌啦。 他們跳得有點亂，衣服又不一致，身型更有點多元化，但加起來，我感覺十分舒服。 我起初認為可能係音樂嘅原因，因為首歌的確好令人愉快。 但我再看其他嘅IKO IKO嘅MTVs，我就知我鍾意呢個片段係因為佢哋嘅舞蹈加上呢個特別嘅音樂。 我先將佢哋嘅片段放第一位（1），然後其他嘅，歌詞放到最後！

（1）IKO IKO BY JUSTIN WELLINGTON DANCE COVER

（2）>IKO IKO in ITALIANO 🇮🇹 TIK TOK DANCE CHALLENGE🇮🇹 BALLA BALLA - Manuel e Claudia B. JOY

（3）IKO IKO SAMBA Line Dance

（4）iko iko dance DNC

（5） IKO IKO SAMBA LINE DANCE//KDR//CHOREO BY YANTI TULUNG//LOKASI REMBONG KAFE RTG

IKO IKO的歌词如下：

当然，任何一组都比我跳得好，哈哈😄

BioNtech COVID19 疫苗 近期资料 10-05-2021

開發首支Covid-19疫苗的德國BioNTech SE公司負責人表示，到2022年年中，可能需要一種新的配方來防止病毒的未來突變。

The head of BioNTech SE that developed the first Covid-19 vaccine, said a new formula is likely to be needed by mid-2022 to protect against future mutations of the virus. (Bloomberg; October 3, 2021) 

輝瑞公司/BioNTech SE疫苗在預防冠狀病毒感染方面的有效性從第二次劑量后六個月的88%下降到47%. 因此，可能需要第三剂。

The effectiveness of the Pfizer Inc /BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47% from 88% six months after taking the second dose, thus there may be a need for booster shots. (Reuters; October 5, 2021) 

歐盟藥品監管機構表示，免疫系統衰弱的人應該從輝瑞-BioNTech或Moderna接受第三劑COVID-19疫苗，但由成員國來決定。

The European Union's drugs regulator said on Monday people with weakened immune systems should get a third dose of a COVID-19 vaccine from Pfizer-BioNTech or Moderna, but left it to member states to decide if the wider population should have a booster. (Reuters; October 4, 2021) 

Merck/Ridgeback Biotherapeutics 宣佈了關於其口服抗病毒藥物molnupiravir的第三階段研究的中期數據。該藥物可使輕度或中度COVID-19的非住院成人患者住院或死亡的風險降低約50%。之后，BioNTech的股价大跌，我不明白，因为，molnupiravir是治疗用，而BioNTech是预防，两者是不同的东西。如果，利用monupiravir来预防，那么，用者可能每天都要服用，相当麻烦。如果，阁下有高见，请分享一下。谢谢

Merck/Ridgeback Biotherapeutics announced positive interim data from a phase III study on their oral antiviral medicine, molnupiravir. The medicine reduced the risk of hospitalization or death by approximately 50% in non-hospitalized adult patients with mild or moderate COVID-19. (ZACKS; October 4, 2021)  (Merck is supposed for treatment, while vaccine is for prevention. If someone uses Merck's for prevention (as an oral vaccine) then someone may need to take it daily. Do you think if this is quite troublesome? I don't understand how Merck's medicine can affect BioNTech's stock value. If you have the answer, please let me know.)

FDAfull批准16歲及以上人群用輝瑞/BioNTech疫苗。但他們尚未完全批准將其用作第3次注射。相反，FDA在緊急使用授權下批准了輝瑞的第3次注射，並批准了尚未申請的全部生物製劑許可證（BLA）。FDA希望以色列提供軍事人員的數據可以澄清接受輝瑞/BioNTechCOVID-19第3次注射对年輕人患心肌炎症的風險（安全性度）。

FDA granted full approval for the Pfizer/BioNTech vaccine for people age 16 and older but they have not yet given full approval for its use as a booster shot. Instead, the FDA approved Pfizer's booster under an emergency use authorization with approval on the full biologics license application (BLA) still pending. FDA are hoping data on Israeli military personnel can help clarify the risk of heart muscle inflammation in younger people who have received Pfizer/BioNTech COVID-19 booster shots. (Reuters; October 1, 2021)

以下是BioNTechCOVID19疫苗的供应分配：

Here tells where BioNTech's vaccine goes:

 

本来，中國应该在7月前批准BioNtech的疫苗。但中國研发的疫苗在預防住院治療方面是有效的，而对Delta變種BioNtech的療效降低到64%。另一方面，中國製藥商正在開發自己的mRNA疫苗。The Wall Street Jounral认为：這些因素可能導致BioNtech疫苗審批的延遲。

China was expected to approve the BioNTech vaccine, by July. Chinese vaccines have proven effective at preventing hospitalizations, while the Delta variant cuts BioNTech’s efficacy down to 64%. On the other hand, Chinese drug makers are developing their own mRNA vaccines. These factors may cause the delay for the BioNTech vaccine approval. (The Wall Street Journal; August 27, 2021)